Lyphe Group, the UK’s leading medical cannabis company, has announced an exclusive partnership with Cronos Australia Limited’s (“Cronos”) wholly-owned subsidiary Burleigh Heads Cannabis Pty Ltd (“BHC”).
Under the agreement, BHC will import and distribute medicinal cannabis products from Lyphe to patients across the whole of Australia via its market leading platform ‘CanView’. As one of the biggest medicinal cannabis companies in the UK, Lyphe Group believes this partnership with Australia’s leading medicinal cannabis company will significantly improve its patients’ access to medicinal cannabis and their quality of life not just in the UK, but now also on the other side of the world.
Cronos is a key player within Australia’s medicinal cannabis industry. Its market-leading CanView platform is a free-to-use, AI-enabled proprietary ecosystem that facilitates the compliant prescription, sale, supply and dispensing of medicinal cannabis products for patients, prescribers, pharmacists and suppliers, such as Lyphe, right across Australia. Cronos believes that the CanView platform provides a wide range of benefits to all medicinal cannabis stakeholders and greatly improves patient access and treatment. These are values shared by Lyphe Group, which is also passionate about making patient access to medicinal cannabis both mainstream and global.
This latest deal strengthens Lyphe Group’s presence in the Australian market, following the launch of its own clinic there earlier this year. The Lyphe Clinic, which sees patients virtually, has so far helped hundreds of patients from across the country access medicinal cannabis products. The team at Lyphe is confident that this latest partnership with another leading, value-driven medicinal cannabis company will help it achieve its vision of making medicinal cannabis accessible globally.
Chris Ashton, Chief Pharmacist at Lyphe Group said: “We are delighted to have signed this deal with Cronos, a leading, innovative global company very similar to ourselves. Cronos echoes our values and shares our passion of bringing medicinal cannabis into the mainstream and making it more accessible to patients, with a similar ambition to become leaders in the sector not only in our own countries, but across Europe and the globe. We are delighted to be growing our presence in Australia and are very much looking forward to working with the Cronos team going forward.”
Guy Headley, Chief Commercial Officer at Cronos said: “We are pleased that Lyphe Group has selected BHC’s Canview platform as the distribution platform of choice. We are looking forward to working with the local Lyphe team to bring a number exciting new products to market at a time when the number of patients seeking these treatments continues to accelerate. With aligned values we see this relationship being a great success moving forward for both of our companies.”